Literature DB >> 17661341

Features predicting unresectability in hepatoblastoma.

Lorenzo D'Antiga1, Francesca Vallortigara, Umberto Cillo, Enrico Talenti, Massimo Rugge, Lucia Zancan, Patrizia Dall'Igna, Gian Luca De Salvo, Giorgio Perilongo.   

Abstract

BACKGROUND: Approximately 20% of patients who have hepatoblastoma (HB) still have unresectable disease after preoperative chemotherapy (POC). In these circumstances, orthotopic liver transplantation (OLT) should be performed 1 month after POC. The authors sought to identify presenting features that would predict unresectability in patients with HB and to provide suggestions for early referral and listing for OLT.
METHODS: Notes, radiology films, and histology from patients who were treated over the previous 20 years were reviewed. Unfeasible resection was defined by bilobar involvement, vascular extension, and metastatic disease after POC. Failed conservative treatment (FCT) was used to categorize patients who were not disease-free with their native liver > or =1 year after surgery.
RESULTS: Of 28 patients who were studied, 14 patients underwent resection, and 10 patients required OLT. Four patients did not undergo any type of surgery because of tumor progression. Overall, the 5-year survival rate was 76% (95% confidence interval, 54.8-89%). Predictors of FCT were multifocality (P = .006), a high pretreatment extent of tumor (PRETEXT) score (III or IV; P = .006), portal vein involvement (P = .02), hepatic vein involvement (P = .02), or vena cava involvement (P = .05). Patients who achieved a curative resection presented at a younger age (median, 0.7 years vs 4.2 years, P = .02). Patients who had multifocal lesions and those who had an alpha-fetoprotein (alphaFP) level <100 ng/mL survived only if they underwent transplantation.
CONCLUSIONS: Patients with HB who were managed by combined chemotherapy and surgery has a high survival rate. Older patients who had multifocal tumors, high PRETEXT scores, involvement of major liver vessels, and alphaFP levels <100 ng/mL were less likely to achieve curative resection. These findings at presentation should lead the clinicians to liaise early with a transplantation center.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661341     DOI: 10.1002/cncr.22876

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  LINC00673 rs11655237 C>T Polymorphism Impacts Hepatoblastoma Susceptibility in Chinese Children.

Authors:  Tianyou Yang; Jiahao Li; Yang Wen; Tianbao Tan; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Yan Zou
Journal:  Front Genet       Date:  2019-05-24       Impact factor: 4.599

Review 2.  How Do Synchronous Lung Metastases Influence the Surgical Management of Children with Hepatoblastoma? An Update and Systematic Review of the Literature.

Authors:  Roberta Angelico; Chiara Grimaldi; Carlo Gazia; Maria Cristina Saffioti; Tommaso Maria Manzia; Aurora Castellano; Marco Spada
Journal:  Cancers (Basel)       Date:  2019-10-31       Impact factor: 6.639

3.  Experience of treating pediatric hepatoblastoma at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia - Timely surgical intervention playing a key role.

Authors:  Ibrahim AlFawaz; Basheer Ahmed; Afshan Ali; Mouhab Ayas; Amani AlKofide; Zakaria Habib; Khawar Siddiqui
Journal:  Int J Pediatr Adolesc Med       Date:  2020-11-13

4.  Prognostic Factors for Event-Free Survival in Pediatric Patients with Hepatoblastoma Based on the 2017 PRETEXT and CHIC-HS Systems.

Authors:  Hee Mang Yoon; Jisun Hwang; Kyung Won Kim; Jung-Man Namgoong; Dae Yeon Kim; Kyung-Nam Koh; Hyery Kim; Young Ah Cho
Journal:  Cancers (Basel)       Date:  2019-09-18       Impact factor: 6.639

5.  Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic Chinese population.

Authors:  Tianbao Tan; Jiahao Li; Yang Wen; Yan Zou; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Tianyou Yang
Journal:  J Cell Mol Med       Date:  2020-11-24       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.